Synspira

Boston
Massachusetts
United States

Tel: 781-235-3060

Email: info@synspira.com

Show jobs for this employer

About Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform for the development of inhaled glycopolymer-based therapeutics in pulmonary indications. Synspira is using proprietary modified polysaccharide molecules to disrupt bacterial biofilms and to help expectorate mucus, exposing otherwise protected bacteria to antibiotics. This new approach to the treatment of disease pathology has the potential to improve pulmonary function and reduce antibiotic resistance in a number of infectious diseases.
YEAR FOUNDED:
2017
LEADERSHIP:
CEO: Shenda Baker, Ph.D.
CFO: Kim Snyder, MBA
CMO: Gregory Fiore MD
PIPELINE:
Please click here for Synspira's pipeline.

9 articles about Synspira